A Case for Private Equity in Sub-Saharan Africa

2014 ◽  
Vol 17 (2) ◽  
pp. 81-83
Author(s):  
David M. Mataen
2012 ◽  
Vol 10 (1) ◽  
pp. 110-124
Author(s):  
Johan Hough ◽  
Andre Parker ◽  
Ernst Neuland

“Africa‟s not for sissies” is what one often hears when discussing business conditions in sub-Saharan Africa (SSA). However, the good news is that the new millennium increasingly exhibits significant trends in support of the notion that a reversal of SSA‟s fortunes is underway: annual GDP growth in the region is well ahead of the global average, civil wars in the region have largely come to an end and, for two years running, private equity investment flows into the region have surpassed that of foreign aid, Africa‟s traditional „crutch‟. Importantly, a small band of early-mover Multinational Corporations (MNCs) are making their presence felt in the region and beginning to make good profits. These firms include the likes of Diageo, The Coca-Cola Company, MTN and SABMiller. The purpose of this article is to research the nature and the changing face of the MNC, impact on globalization and Foreign Direct Investment (FDI), and some MNC strategies to enter foreign markets.


2020 ◽  
Author(s):  

Abstract Lake Harvest Aquaculture (Pvt) Ltd was first developed into a freshwater tilapia fish farm business in 1996 on premises that originally farmed freshwater prawns owned by one of Zimbabwe's food companies, Cairns Foods Ltd. The farm was set up in 1997 and, ten years later, has grown to a 3000-tonne fish farm where tilapia are produced primarily for processing and export to European and regional markets. The original targeted projections for production and net income of the farm were proving accurate until 2001 when the macro-economy began to shrink. Low production on crop farms due to inadequate resources and drought brought a shortage of raw materials to the feed manufacturing companies. The continuous downward trend in feed production affected the company as it failed to support its growing fish biomass. The feed and economy problems resulted in a decision by the board to stop expansion of the business in 2002. Lake Harvest business was set up at a cost of US $10,000,000. The business was externally funded by the Commonwealth Development Corporation (CDC Group plc) and Comafin, a pan-African private equity fund, before the share holding structure changed in 2002. The major costs were encountered on the installation and mooring of cages, and the construction of a fish processing factory. Six sites were installed, each costing around US $350,000, including boats. The processing factory cost around US $4,000,000. The objectives of this case study are to: * Provide a scenario and overview of Lake Harvest Aquaculture as a company growing tilapia in cages in Lake Kariba, Zimbabwe. * Provide a means of assessment and learning for those considering developing cage-based aquaculture in sub-Saharan Africa. All of the main activities carried out at Lake Harvest will be described in the same sequence as followed on-farm; production, management, and sale of the final product: * Breeding * Feeding * Sampling * Diving * Harvesting * Processing * Marketing.


Subject Outlook for private equity in sub-Saharan Africa. Significance Private equity (PE) investments in sub-Saharan Africa (SSA) grew to 8.1 billion dollars in 2014 from 1.5 billion dollars in 2009, according to African Private Equity and Venture Capital Association data. Inexperience in relatively risky markets and lack of 'investment ready' prospects has held back major foreign PE firms, but this is beginning to change. Impacts Nigerian billionaire Aliko Dangote may increase his investments non-SSA ventures to reduce his exposure to slowing regional GDP growth. Disappointing 'middle class' spending growth could dampen investor interest in mainstream retail opportunities such as shopping malls. Rising property prices, particularly in first-tier SSA cities, will attract substantial PE investment, particularly by South African firms.


Subject Outlook for private equity in sub-Saharan Africa. Significance Private equity (PE) firm Actis on June 6 announced that it has raised 500 million dollars for its third African property fund, exceeding its 400-million-dollar target. The fund will invest in office, retail and industrial projects. The region's PE scene is buoyant, despite market jitters caused by the economic downturn. Last year, PE firms raised a record 4.3 billion dollars, up from 2.0 billion dollars in 2014 and 3.5 billion in 2013. Impacts South Africa's share of PE investment will decrease owing to adverse sentiment linked to an expected credit rating downgrade. State-backed UK investor CDC's 140-million-dollar investment in ARM Cement will boost East Africa's regional cement industry. Spurred by low domestic growth, Nigerian and South African investors will seek higher returns in neighbouring states. Efforts to cut costs in PE investors' portfolio firms by dismissing employees will face resistance in states with strong labour unions.


2017 ◽  
Vol 1 (6) ◽  
pp. 533-537
Author(s):  
Lorenz von Seidlein ◽  
Borimas Hanboonkunupakarn ◽  
Podjanee Jittmala ◽  
Sasithon Pukrittayakamee

RTS,S/AS01 is the most advanced vaccine to prevent malaria. It is safe and moderately effective. A large pivotal phase III trial in over 15 000 young children in sub-Saharan Africa completed in 2014 showed that the vaccine could protect around one-third of children (aged 5–17 months) and one-fourth of infants (aged 6–12 weeks) from uncomplicated falciparum malaria. The European Medicines Agency approved licensing and programmatic roll-out of the RTSS vaccine in malaria endemic countries in sub-Saharan Africa. WHO is planning further studies in a large Malaria Vaccine Implementation Programme, in more than 400 000 young African children. With the changing malaria epidemiology in Africa resulting in older children at risk, alternative modes of employment are under evaluation, for example the use of RTS,S/AS01 in older children as part of seasonal malaria prophylaxis. Another strategy is combining mass drug administrations with mass vaccine campaigns for all age groups in regional malaria elimination campaigns. A phase II trial is ongoing to evaluate the safety and immunogenicity of the RTSS in combination with antimalarial drugs in Thailand. Such novel approaches aim to extract the maximum benefit from the well-documented, short-lasting protective efficacy of RTS,S/AS01.


1993 ◽  
Vol 47 (3) ◽  
pp. 555-556
Author(s):  
Lado Ruzicka

Sign in / Sign up

Export Citation Format

Share Document